Aspyrian Therapeutics Inc. announces successful advances in RM-1929 clinical development

Aspyrian Therapeutics Inc. announces successful advances in RM-1929 clinical development in recurrent Head and Neck Cancer, including Fast Track designation granted by the FDA, initiation of clinical studies in Japan, and plans to start pivotal studies, which will incorporate the evaluation of anti-cancer immune responses, in early 2018.

• Source: Prnewswire
• 757
• January 19, 2018